U.S. stock market update: Rafael-B down 17.28%

U.S. Stock Market Midday Update

Stocks with High Trading Volume in the Industry

Eli Lilly fell 1.26%, with increased trading volume. Based on recent important news:

1. On September 17, Eli Lilly's oral medication Orforglipron outperformed Novo Nordisk's product in diabetes research, solidifying its market competitive position, with the stock price rising 0.8% in pre-market trading. Source: Eli Lilly press release.

2. On September 17, JP Morgan lowered Eli Lilly's target price from $110 to $105, maintaining an "Overweight" rating, reflecting the market's cautious attitude towards its future growth. Source: JP Morgan report.

3. On September 18, Morgan Stanley maintained an "Overweight" rating for Eli Lilly, with a target price of $102.8, emphasizing Orfor's excellent performance in weight loss and safety. Source: Morgan Stanley research report. The Federal Reserve's interest rate cut has increased market volatility.

Johnson & Johnson rose 1.04%, with increased trading volume. Based on recent important news:

1. On September 17, Johnson & Johnson's experimental psoriasis drug showed potential against Bristol-Myers Squibb's treatment regimen, driving the stock price up. Data indicated that the drug outperformed competitors in skin clearance rates. Source: Company announcement.

2. On September 18, Johnson & Johnson's investment and capacity expansion plans in the Chinese market gained attention, particularly the upgrade project in the Suzhou industrial park, boosting market confidence. Source: Company statement.

3. On September 19, JP Morgan raised Johnson & Johnson's target price to $200, maintaining a neutral rating, reflecting the market's optimistic expectations for the company's future performance. Source: Analyst report. Investment in the healthcare industry continues to grow, enhancing market confidence.

Pfizer fell 0.95%, with a trading volume of $880 million. Based on recent important news:

1. On September 18, Pfizer's drug vepdegestrant, developed in collaboration with Arvinas, received FDA Fast Track designation and submitted a new drug application. This news caused stock price fluctuations, as the market is optimistic about the drug's commercialization prospects. Source: FDA announcement.

2. On September 18, BNB's market capitalization surpassed Pfizer's, ranking 155th globally. This news raised market attention towards Pfizer's market value, potentially affecting investor confidence. Source: 8marketcap.

3. On September 17, analysts maintained a "Hold" rating for Pfizer, with a target price of $28, indicating a 17.15% upside from current levels. This rating may influence investors' short-term expectations for Pfizer. Source: J.P. Morgan report. Frequent collaborations in the biopharmaceutical industry's innovative drug sector.

Stocks with High Market Capitalization in the Industry

Novo Nordisk fell 0.83%. Based on recent key news:

1. On September 18, Novo Nordisk announced the results of its late-stage trial for its once-daily weight loss drug, showing significant weight loss effects comparable to the injectable drug Wegovy, with the stock price rising 7.4%

2. On September 18, Novo Nordisk's stock price increase expanded to 4.7% after the REACH study results were announced.

3. On September 17, Novo Nordisk announced plans to fully launch oral semaglutide in the United States early next year, demonstrating a positive market strategy. The pharmaceutical industry is performing strongly overall